SCHEDULE 13G/A: Invus Entities Disclose 2.8% Beneficial Stake in Gossamer Bio, Inc.
Beneficial Ownership Disclosure
Multiple Invus-affiliated entities and Raymond Debbane have filed an amended Schedule 13G, disclosing a collective beneficial ownership of 2.8% in Gossamer Bio, Inc. as of December 31, 2024.
Summary
- Invus Public Equities, L.P., along with its controlling entities Invus Public Equities Advisors, LLC, Invus Global Management, LLC, and Siren, L.L.C., and ultimately Raymond Debbane, collectively reported beneficial ownership of 6,258,880 shares of Gossamer Bio, Inc. Common Stock.
- This aggregate beneficial ownership represents 2.8% of Gossamer Bio, Inc.'s outstanding common stock.
- The reported shares include 5,208,968 directly held shares, call options exercisable for 207,000 shares with an exercise price of $2.00 and an expiration date of January 17, 2025, and warrants to purchase 842,912 shares with an exercise price of $2.04 and an expiration date of July 24, 2028.
- The percentage of ownership was calculated based on 226,604,137 shares outstanding as of November 4, 2024, plus the 842,912 shares issuable upon exercise of the warrants.
- Avicenna Life Sci Master Fund LP, Avicenna Life Sci Master GP LLC, and Ulys, L.L.C. reported 0% beneficial ownership, despite being part of the broader control structure under Raymond Debbane.
Sentiment
Score: 5
Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects. It is a neutral regulatory update.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of beneficial ownership by an investment group in a publicly traded biotechnology company. It does not provide specific insights into broader industry trends or competitive landscape beyond the investment itself.
Key Dates
| Date | Description |
|---|---|
| 2024-11-04 | Date as of which 226,604,137 shares of Gossamer Bio, Inc. Common Stock were reported outstanding in the company's Form 10-Q. |
| 2024-11-07 | Date Gossamer Bio, Inc. filed its Quarterly Report on Form 10-Q with the SEC. |
| 2024-12-31 | Date of event which requires the filing of this Schedule 13G Amendment No. 3. |
| 2025-01-17 | Expiration date for call options exercisable for 207,000 shares. |
| 2025-02-12 | Date the Schedule 13G Amendment No. 3 was signed by Raymond Debbane on behalf of all reporting persons. |
| 2028-07-24 | Expiration date for warrants to purchase 842,912 shares. |
Keywords
Gossamer Bio, Invus Public Equities, Raymond Debbane, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Biotechnology, Investment, Shareholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.